“Lenvima suggests a new option for radioiodine-refractory thyroid cancer”

Published: 2016-03-15 10:58:34

Updated: 2016-03-15 10:58:34

A new treatment option was added in the radioiodine-refractory local recurrent or progressive differentiated thyroid cancer treatment.

Eisai Korea(CEO Hong-byung Goh) held a press conference to celebrate the launch of Lenvima, a radioiodine-refractory local recurrent or progressive differentiated thyroid cancer treatment, on the 11^th, and announced its Phase 3 clinical trial result.

Announc...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.